Table 1.
FDA approved anti-angiogenic compounds for solid tumors. * Not licensed yet
| Molecular target | Therapy | Malignancy | Improvement in (months) | |
|---|---|---|---|---|
| PFS | OS | |||
| VEGF-A | Bevacizumab | Glioblastoma | N/A | 0.5 |
|
| ||||
| VEGF-A | Bevacizumab + Fluoropyrimidine based chemotherapy | Metastatic colorectal cancer | 1.7 | 1.4 |
|
| ||||
| VEGF-A | Bevacizumab + FOLFOX4 | Metastatic colorectal cancer | 2.6 | 2.1 |
|
| ||||
| VEGF-A | Bevacizumab + Irinotecan + fluorouracil + leucovorin | Metastatic colorectal cancer | 4.4 | 4.7 |
|
| ||||
| VEGF-A | Bevacizumab + Paclitaxel or Cisplatin, Topotecan | Recurrent metastatic cervical cancer | 2.3 | 3.7 |
|
| ||||
| VEGF-A | Bevacizumab + Carboplatin + Paclitaxel | Recurrent metastatic non-squamous NSCLC | 1.7 | 2 |
|
| ||||
| VEGF-A | Bevacizumab + IFN-α | Advanced renal cell carcinoma | 4.8 | NS |
|
| ||||
| VEGF-A | Bevacizumab + pemetrexed + cisplatin | Pleural mesothelioma | 2.7 | |
|
| ||||
| VEGF-A | Bevacizumab + Paclitaxel or Pegylated liposomal Doxorubicin or Topotecan | Peritoneal cancer or recurrent epithelial Ovarian cancer fallopian tube cancer | 3.8 | 5.3 |
|
| ||||
| VEGF-A | Bevacizumab + Paclitaxel | Metastatic HER2- inflammatory breast cancer | 1.7 | 7.9 |
|
| ||||
| VEGF-A, VEGF-B, PlGF | Aflibercept + FOLFIRI | Metastatic colorectal cancer | 2.2 | 1.4 |
|
| ||||
| VEGFR-2 | Ramucirumab | Gastro-esophageal junction adenocarcinoma or Gastric adenocarcinoma | 0.8 | 1.4 |
|
| ||||
| VEGFR-2 | Ramucirumab + Paclitaxel | Advanced gastro-esophageal junction adenocarcinoma or gastric adenocarcinoma | 1.5 | 2.2 |
|
| ||||
| VEGFR-2 | Ramucirumab + Docetaxel | Metastatic NSCLC | N/A | 1.4 |
|
| ||||
| VEGFR-2 | Ramucirumab + FOLFIRI | Metastatic colorectal carcinoma | 1.2 | 1.6 |
|
| ||||
| VEGFR-1–2, PDGFR-α/β | Sunitinib | Pancreatic neuroendocrine tumors | 4.8 | N/A |
|
| ||||
| VEGFR-1–2, PDGFR-α/β | Sunitinib | Gastrointestinal stromal tumors | 4.5 | NS |
|
| ||||
| VEGFR-1–2, PDGFR-α/β | Sunitinib + IFN-α | Advanced clear cell carcinoma Renal cancer | 25.3 | N/A |
|
| ||||
| VEGFR-1–3, PDGFR-α, FGFR1–4 | Lenvatinib | Recurrent or metastatic radioactive iodine refractory differentiated thyroid carcinoma | 14.7 | N/A |
|
| ||||
| VEGFR-1–3, PDGFR-α, FGFR1–4 | Lenvatinib | Advanced hepatocellular carcinoma | * | * |
|
| ||||
| VEGFR-1–3, PDGFR-α, FGFR1–4 | Lenvatinib + Everolimus | Advanced renal cell carcinoma | 9.1 | NS |
|
| ||||
| VEGFR-2 | Vandetanib | Advanced differentiated thyroid carcinoma | 6.2 | N/A |
|
| ||||
| VEGFR-2, PDGFRβ | Sorafenib | Advanced hepatocellular Carcinoma | NS | 2.8 |
|
| ||||
| VEGFR-2, PDGFRβ | Sorafenib | Advanced renal cell carcinoma | 2.7 | NS |
|
| ||||
| VEGFR-2, PDGFRβ | Sorafenib | Recurrent or metastatic differentiated thyroid cancer | 5.0 | N/A |
|
| ||||
| VEGFR-1–3, PDGFRβ, FGFR-1–2 | Pazopanib hydrochloride | Advanced soft tissue carcinoma | 6.2 | N/A |
|
| ||||
| VEGFR-1–3, PDGFRβ, FGFR-1–2 | Pazopanib hydrochloride | Advanced renal cell carcinoma | 5.0 | N/A |
|
| ||||
| VEGFR-1–3, PDGFRβ | Axitinib | Advanced renal cell carcinoma | 6.2 | N/A |
|
| ||||
| VEGFR-1–3, PDGFRβ, FGFR-1–2 | Regorafenib | Advanced gastrointestinal stromal tumors | 2.2 | 1.4 |
|
| ||||
| VEGFR-1–3, PDGFRβ, FGFR-1–2 | Regorafenib | Chemo-refractory metastatic colorectal cancer | 0.2 | 1.4 |
|
| ||||
| VEGFR-1–3, PDGFRβ, FGFR-1–2 | Regorafenib* | Refractory hepatocellular carcinoma | 7.2 | NS |
|
| ||||
| VEGFR-1–3 | Cediranib + carboplatin or cisplatin | Ovarian cancer | 1.1 | ** |
|
| ||||
| VEGFR-2, Tie2 | Cabozantinib | Refractory advanced renal carcinoma | 3.6 | 4.9 |
|
| ||||
| VEGFR-2, Tie2 | Cabozantinib | Metastatic medullary thyroid cancer | 7.2 | NS |
|
| ||||
| VEGFR-2, Tie2 | Cabozantinib | Pancreatic neuroendocrine tumors | ** | ** |
Current list of FDA approved anti-angiogenic compounds for solid tumors.
*
Significantly improved progression free-survival and overall survival, but not licensed yet for FDA approval,
**
Clinical trail is still recruiting patients and data needs to be fully analyzed, but the result is promising and therefore is likely to be FDA approved